Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Epilepsy is common in early childhood. In this age group it is associated with high rates of therapy-resistance, and with cognitive, motor, and behavioural comorbidity. A large number of genes, with wide ranging functions, are implicated in its aetiology, especially in those with therapy-resistant seizures. Identifying the more common single-gene epilepsies will aid in targeting resources, the prioritization of diagnostic testing and development of precision therapy. Previous studies of genetic testing in epilepsy have not been prospective and population-based. Therefore, the population-incidence of common genetic epilepsies remains unknown. The objective of this study was to describe the incidence and phenotypic spectrum of the most common single-gene epilepsies in young children, and to calculate what proportion are amenable to precision therapy. This was a prospective national epidemiological cohort study. All children presenting with epilepsy before 36 months of age were eligible. Children presenting with recurrent prolonged (>10 min) febrile seizures; febrile or afebrile status epilepticus (>30 min); or with clusters of two or more febrile or afebrile seizures within a 24-h period were also eligible. Participants were recruited from all 20 regional paediatric departments and four tertiary children’s hospitals in Scotland over a 3-year period. DNA samples were tested on a custom-designed 104-gene epilepsy panel. Detailed clinical information was systematically gathered at initial presentation and during follow-up. Clinical and genetic data were reviewed by a multidisciplinary team of clinicians and genetic scientists. The pathogenic significance of the genetic variants was assessed in accordance with the guidelines of UK Association of Clinical Genetic Science (ACGS). Of the 343 patients who met inclusion criteria, 333 completed genetic testing, and 80/333 (24%) had a diagnostic genetic finding. The overall estimated annual incidence of single-gene epilepsies in this well-defined population was 1 per 2120 live births (47.2/100 000; 95% confidence interval 36.9–57.5). PRRT2 was the most common single-gene epilepsy with an incidence of 1 per 9970 live births (10.0/100 000; 95% confidence interval 5.26–14.8) followed by SCN1A: 1 per 12 200 (8.26/100 000; 95% confidence interval 3.93–12.6); KCNQ2: 1 per 17 000 (5.89/100 000; 95% confidence interval 2.24–9.56) and SLC2A1: 1 per 24 300 (4.13/100 000; 95% confidence interval 1.07–7.19). Presentation before the age of 6 months, and presentation with afebrile focal seizures were significantly associated with genetic diagnosis. Single-gene disorders accounted for a quarter of the seizure disorders in this cohort. Genetic testing is recommended to identify children who may benefit from precision treatment and should be mainstream practice in early childhood onset epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function (LOF) missense or truncating variants cause Dravet syndrome, the prototypic DEE 13,27 , and also the non-DEE syndrome of Genetic Epilepsy with Febrile Seizures Plus (GEFS+) 28 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The incidence of syndromes associated with de novo genetic variants is likely to be similar around the world 13 ; whereas, recessive causes occur more frequently in populations with high rates of consanguinity 14 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., et al. (2017) · Epilepsia · doi:10.1111/epi.13709 · Cited by 5,054 · cited 1×
“The concept of the ‘developmental and epileptic encephalopathy’ (DEE) recognizes that in children presenting with early-onset epilepsy, neurodevelopmental comorbidity may be attributable to both the underlying cause and to the detrimental effects of uncontrolled epileptic activity (Scheffer et al., 2017).”
Self-citationIncidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935–1984
Hauser, W. A., Annegers, J. F., & Kurland, L. T. (1993) · Epilepsia · doi:10.1111/j.1528-1157.1993.tb02586.x · Cited by 2,073
Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies
Fiest, K. M., Sauro, K. M., Wiebe, S., Patten, S. B., Kwon, C.-S., Dykeman, J., Pringsheim, T., Lorenzetti, D. L., & Jetté, N. (2017) · Neurology · doi:10.1212/wnl.0000000000003509 · Cited by 1,902
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Estimation of the burden of active and life-time epilepsy: a meta-analytic approach
Ngugi, A. K., Bottomley, C., Kleinschmidt, I., Sander, J. W., & Newton, C. R. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02481.x · Cited by 1,447 · cited 1×
“, 2017) and that 50–65 million individuals are affected worldwide (Ngugi et al., 2010; Fiest et al., 2017).”
A Potassium Channel Mutation in Neonatal Human Epilepsy
Biervert, C., Schroeder, B. C., Kubisch, C., Berkovic, S. F., Propping, P., Jentsch, T. J., & Steinlein, O. K. (1998) · Science · doi:10.1126/science.279.5349.403 · Cited by 1,073 · cited 1×
“The literature describes two distinct phenotypes associated with KCNQ2 variants: a self-limited familial neonatal seizure phenotype (Biervert et al., 1998; Singh et al., 2003) and a severe neonatal-onset developmental and epileptic encephalopathy (Weckhuysen et al.”
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015 · cited 2×
“Cannabidiol also has efficacy in Lennox Gastaut syndrome (French et al., 2017; Devinsky et al., 2018), an epilepsy with varied aetiologies.”
Self-citationDevinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000 · cited 1×
“In Dravet syndrome cannabidiol demonstrates efficacy (Devinsky et al. , 2017); however, there is no biological reason why cannabidiol should be specifically effective in this condition because it does not appear to act on sodium channels or GABA receptors (Devinsky et al. , 2014).”
Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2
Escayg, A., MacDonald, B. T., Meisler, M. H., Baulac, S., Huberfeld, G., An-Gourfinkel, I., Brice, A., LeGuern, E., Moulard, B., Chaigne, D., et al. (2000) · Nature Genetics · doi:10.1038/74159 · Cited by 996
Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders
Wolff, M., Johannesen, K. M., Hedrich, U. B. S., Masnada, S., Rubboli, G., Gardella, E., Lesca, G., Ville, D., Milh, M., Villard, L., et al. (2017) · Brain · doi:10.1093/brain/awx054 · Cited by 600
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568 · cited 2×
“Precision therapy approaches have driven randomized therapeutic trials including stiripentol (Chiron et al., 2000) and cannabidiol (Devinsky et al.”
The spectrum of SCN1A-related infantile epileptic encephalopathies
Harkin, L. A., McMahon, J. M., Iona, X., Dibbens, L., Pelekanos, J. T., Zuberi, S. M., Sadleir, L. G., Andermann, E., Gill, D., Farrell, K., et al. (2007) · Brain · doi:10.1093/brain/awm002 · Cited by 531
Self-citationKCNQ2 encephalopathy: Emerging phenotype of a neonatal epileptic encephalopathy
Weckhuysen, S., Mandelstam, S., Suls, A., Audenaert, D., Deconinck, T., Claes, L. R. F., Deprez, L., Smets, K., Hristova, D., Yordanova, I., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22644 · Cited by 514
Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., & Dulac†, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01413.x · Cited by 467
De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies
Appenzeller, S., Balling, R., Barisic, N., Baulac, S., Caglayan, H., Craiu, D., De Jonghe, P., Depienne, C., Dimova, P., Djémié, T., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.08.013 · Cited by 439
Sawyer, S. L., Hartley, T., Dyment, D. A., Beaulieu, C. L., Schwartzentruber, J., Smith, A., Bedford, H. M., Bernard, G., Bernier, F. P., Brais, B., et al. (2016) · Clinical Genetics · doi:10.1111/cge.12654 · Cited by 383
Global cognitive function in children with epilepsy: A community‐based study
Berg, A. T., Langfitt, J. T., Testa, F. M., Levy, S. R., DiMario, F., Westerveld, M., & Kulas, J. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2007.01461.x · Cited by 373
Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
Brunklaus, A., Ellis, R., Reavey, E., Forbes, G. H., & Zuberi, S. M. (2012) · Brain · doi:10.1093/brain/aws151 · Cited by 366 · cited 2×
“As some genetic epilepsies initially present with prolonged febrile seizures (Brunklaus et al., 2012; Higurashi et al., 2013; Ebrahimi-Fakhari et al., 2015) children with status, clusters of febrile seizures, and recurrent prolonged febrile seizures were included.”
Self-citationHelbig, K. L., Farwell Hagman, K. D., Shinde, D. N., Mroske, C., Powis, Z., Li, S., Tang, S., & Helbig, I. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.186 · Cited by 363
Targeted next generation sequencing as a diagnostic tool in epileptic disorders
Lemke, J. R., Riesch, E., Scheurenbrand, T., Schubach, M., Wilhelm, C., Steiner, I., Hansen, J., Courage, C., Gallati, S., Bürki, S., et al. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03516.x · Cited by 332
Singh, N. A. (2003) · Brain · doi:10.1093/brain/awg286 · Cited by 310
Lindy, A. S., Stosser, M. B., Butler, E., Downtain‐Pickersgill, C., Shanmugham, A., Retterer, K., Brandt, T., Richard, G., & McKnight, D. A. (2018) · Epilepsia · doi:10.1111/epi.14074 · Cited by 305
Early and effective treatment of KCNQ 2 encephalopathy
Pisano, T., Numis, A. L., Heavin, S. B., Weckhuysen, S., Angriman, M., Suls, A., Podesta, B., Thibert, R. L., Shapiro, K. A., Guerrini, R., et al. (2015) · Epilepsia · doi:10.1111/epi.12984 · Cited by 301
KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine
Milligan, C. J., Li, M., Gazina, E. V., Heron, S. E., Nair, U., Trager, C., Reid, C. A., Venkat, A., Younkin, D. P., Dlugos, D. J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24128 · Cited by 290
De novo variants in neurodevelopmental disorders with epilepsy
EuroEPINOMICS RES Consortium, Heyne, H. O., Singh, T., Stamberger, H., Abou Jamra, R., Caglayan, H., Craiu, D., De Jonghe, P., Guerrini, R., Helbig, K. L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0143-7 · Cited by 289
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Devinsky, O., Nabbout, R., Miller, I., Laux, L., Zolnowska, M., Wright, S., & Roberts, C. (2019) · Epilepsia · doi:10.1111/epi.14628 · Cited by 271
The evolving spectrum of PRRT2-associated paroxysmal diseases
Ebrahimi-Fakhari, D., Saffari, A., Westenberger, A., & Klein, C. (2015) · Brain · doi:10.1093/brain/awv317 · Cited by 270
Targeted treatment of migrating partial seizures of infancy with quinidine
Bearden, D., Strong, A., Ehnot, J., DiGiovine, M., Dlugos, D., & Goldberg, E. M. (2014) · Annals of Neurology · doi:10.1002/ana.24229 · Cited by 258
Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: A prospective cohort study
Berg, A. T., Zelko, F. A., Levy, S. R., & Testa, F. M. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1b55 · Cited by 249
Incidence of Dravet Syndrome in a US Population
Wu, Y. W., Sullivan, J., McDaniel, S. S., Meisler, M. H., Walsh, E. M., Li, S. X., & Kuzniewicz, M. W. (2015) · Pediatrics · doi:10.1542/peds.2015-1807 · Cited by 248 · cited 1×
“California (1 per 20 900 live births) (Wu et al., 2015) and in Denmark (1 per 22 000 live births) (Bayat et al.”
Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation
Kato, M., Yamagata, T., Kubota, M., Arai, H., Yamashita, S., Nakagawa, T., FujII, T., Sugai, K., Imai, K., Uster, T., et al. (2013) · Epilepsia · doi:10.1111/epi.12200 · Cited by 226
Trump, N., McTague, A., Brittain, H., Papandreou, A., Meyer, E., Ngoh, A., Palmer, R., Morrogh, D., Boustred, C., Hurst, J. A., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103263 · Cited by 215
Successful use of fenfluramine as an add‐on treatment for Dravet syndrome
Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03495.x · Cited by 210
A roadmap for precision medicine in the epilepsies
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00199-4 · Cited by 204
GLUT1 deficiency syndrome 2013: Current state of the art
De Giorgis, V., & Veggiotti, P. (2013) · Seizure · doi:10.1016/j.seizure.2013.07.003 · Cited by 180
Glucose transporter type I deficiency syndrome: Epilepsy phenotypes and outcomes
Pong, A. W., Geary, B. R., Engelstad, K. M., Natarajan, A., Yang, H., & De Vivo, D. C. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03592.x · Cited by 170
Capovilla, G., Mastrangelo, M., Romeo, A., & Vigevano, F. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01963.x · Cited by 168
Ketogenic Diet in Patients with Dravet Syndrome
Caraballo, R. H., Cersósimo, R. O., Sakr, D., Cresta, A., Escobal, N., & Fejerman, N. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.05705.x · Cited by 165
de Lange, I. M., Gunning, B., Sonsma, A. C. M., van Gemert, L., van Kempen, M., Verbeek, N. E., Nicolai, J., Knoers, N. V. A. M., Koeleman, B. P. C., & Brilstra, E. H. (2018) · Epilepsia · doi:10.1111/epi.14191 · Cited by 161
Early-life epilepsies and the emerging role of genetic testing
Berg, A. T., Coryell, J., Saneto, R. P., Grinspan, Z. M., Alexander, J. J., Kekis, M., Sullivan, J. E., Wirrell, E. C., Shellhaas, R. A., Mytinger, J. R., et al. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.1743 · Cited by 156 · cited 1×
“Participants were recruited from 17 epilepsy centres in the USA (Berg et al., 2017).”
Defining the phenotypic spectrum of SLC6A1 mutations
Johannesen, K. M., Gardella, E., Linnankivi, T., Courage, C., de Saint Martin, A., Lehesjoki, A., Mignot, C., Afenjar, A., Lesca, G., Abi‐Warde, M., et al. (2018) · Epilepsia · doi:10.1111/epi.13986 · Cited by 150
Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine
Mullen, S. A., Carney, P. W., Roten, A., Ching, M., Lightfoot, P. A., Churilov, L., Nair, U., Li, M., Berkovic, S. F., Petrou, S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004769 · Cited by 147
Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK
Baxter, P. (1999) · Archives of Disease in Childhood · doi:10.1136/adc.81.5.431 · Cited by 144
Boerma, R. S., Braun, K. P., van de Broek, M. P. H., van Berkestijn, F. M. C., Swinkels, M. E., Hagebeuk, E. O., Lindhout, D., van Kempen, M., Boon, M., Nicolai, J., et al. (2016) · Neurotherapeutics · doi:10.1007/s13311-015-0372-8 · Cited by 144
Olson, H. E., Kelly, M., LaCoursiere, C. M., Pinsky, R., Tambunan, D., Shain, C., Ramgopal, S., Takeoka, M., Libenson, M. H., Julich, K., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24883 · Cited by 142
Wirrell, E., Wong‐Kisiel, L., Mandrekar, J., & Nickels, K. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03562.x · Cited by 138
Glucose Transporter 1 Deficiency as a Treatable Cause of Myoclonic Astatic Epilepsy
Mullen, S. A., Marini, C., Suls, A., Mei, D., Della Giustina, E., Buti, D., Arsov, T., Damiano, J., Lawrence, K., De Jonghe, P., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.102 · Cited by 138
Bayat, A., Hjalgrim, H., & Møller, R. S. (2015) · Epilepsia · doi:10.1111/epi.12927 · Cited by 120
Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial
Coppola, G., Capovilla, G., Montagnini, A., Romeo, A., Spano, M. C., Tortorella, G., Veggiotti, P., Viri, M., & Pascotto, A. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(02)00010-4 · Cited by 119
Use of dietary therapies amongst patients with GLUT1 deficiency syndrome
Kass, H. R., Winesett, S. P., Bessone, S. K., Turner, Z., & Kossoff, E. H. (2016) · Seizure · doi:10.1016/j.seizure.2016.01.011 · Cited by 117
Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency
Arsov, T., Mullen, S. A., Damiano, J. A., Lawrence, K. M., Huh, L. L., Nolan, M., Young, H., Thouin, A., Dahl, H. M., Berkovic, S. F., et al. (2012) · Epilepsia · doi:10.1111/epi.12007 · Cited by 116
An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy
Striano, P., Coppola, A., Pezzella, M., Ciampa, C., Specchio, N., Ragona, F., Mancardi, M. M., Gennaro, E., Beccaria, F., Capovilla, G., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000265222.24102.db · Cited by 116
A population‐based cost‐effectiveness study of early genetic testing in severe epilepsies of infancy
Howell, K. B., Eggers, S., Dalziel, K., Riseley, J., Mandelstam, S., Myers, C. T., McMahon, J. M., Schneider, A., Carvill, G. L., Mefford, H. C., et al. (2018) · Epilepsia · doi:10.1111/epi.14087 · Cited by 114 · cited 1×
“, 2018), or $7047 US dollars (Howell et al., 2018) per diagnosis when compared with investigation programs that involved extensive imaging and metabolic testing prior to genetic testing.”
Palmer, E. E., Schofield, D., Shrestha, R., Kandula, T., Macintosh, R., Lawson, J. A., Andrews, I., Sampaio, H., Johnson, A. M., Farrar, M. A., et al. (2018) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.355 · Cited by 113 · cited 1×
“Recent economic analyses have demonstrated that the application of early high throughput genetic testing could save $5236 Australian dollars (Palmer et al., 2018), or $7047 US dollars (Howell et al.”
Gaily, E., Lommi, M., Lapatto, R., & Lehesjoki, A. (2016) · Epilepsia · doi:10.1111/epi.13514 · Cited by 112
Millichap, J. J., Miceli, F., De Maria, M., Keator, C., Joshi, N., Tran, B., Soldovieri, M. V., Ambrosino, P., Shashi, V., Mikati, M. A., et al. (2017) · Epilepsia · doi:10.1111/epi.13601 · Cited by 103 · cited 1×
“Post-neonatal presentation with KCNQ2 -related seizures has been reported before (Millichap et al. , 2017; Zeng et al. , 2018).”
Larsen, J., Johannesen, K. M., Ek, J., Tang, S., Marini, C., Blichfeldt, S., Kibæk, M., von Spiczak, S., Weckhuysen, S., Frangu, M., et al. (2015) · Epilepsia · doi:10.1111/epi.13222 · Cited by 101
Anagnostou, M., Ng, Y. S., Taylor, R. W., & McFarland, R. (2016) · Epilepsia · doi:10.1111/epi.13508 · Cited by 101
A population‐based study of newly diagnosed epilepsy in infants
Eltze, C. M., Chong, W. K., Cox, T., Whitney, A., Cortina‐Borja, M., Chin, R. F. M., Scott, R. C., & Cross, J. H. (2013) · Epilepsia · doi:10.1111/epi.12046 · Cited by 90
Effectiveness of antiepileptic therapy in patients with PCDH19 mutations
Lotte, J., Bast, T., Borusiak, P., Coppola, A., Cross, J. H., Dimova, P., Fogarasi, A., Graneß, I., Guerrini, R., Hjalgrim, H., et al. (2016) · Seizure · doi:10.1016/j.seizure.2016.01.006 · Cited by 78
Paroxysmal kinesigenic dyskinesia
Huang, X., Wang, T., Wang, J., Liu, X., Che, X., Li, J., Mao, X., Zhang, M., Bi, G., Li, W., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002079 · Cited by 77
The clinical utility of an SCN1A genetic diagnosis in infantile‐onset epilepsy
BRUNKLAUS, A., DORRIS, L., ELLIS, R., REAVEY, E., LEE, E., FORBES, G., APPLETON, R., CROSS, J. H., FERRIE, C., HUGHES, I., et al. (2013) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12030 · Cited by 71
Self-citationStiripentol efficacy and safety in Dravet syndrome: a 12‐year observational study
Myers, K. A., Lightfoot, P. A., Patil, S., Cross, J. H., & Scheffer, I. E. (2018) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.13704 · Cited by 71
Abdelnour, E., Gallentine, W. B., McDonald, M., Sachdev, M., Jiang, Y., & Mikati, M. A. (2017) · Seizure · doi:10.1016/j.seizure.2017.11.017 · Cited by 69
From splitting GLUT1 deficiency syndromes to overlapping phenotypes
Hully, M., Vuillaumier‐Barrot, S., Bizec, C. L., Boddaert, N., Kamińska, A., Lascelles, K., de Lonlay, P., Cancès, C., Portes, V. D., Roubertie, A., et al. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.06.007 · Cited by 68
Lim, Z., Wong, K., Olson, H. E., Bergin, A. M., Downs, J., & Leonard, H. (2017) · Epilepsia · doi:10.1111/epi.13813 · Cited by 67
Peng, J., Pang, N., Wang, Y., Wang, X., Chen, J., Xiong, J., Peng, P., Zhu, C., Kessi, M. B., He, F., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12869 · Cited by 63
Higurashi, N., Nakamura, M., Sugai, M., Ohfu, M., Sakauchi, M., Sugawara, Y., Nakamura, K., Kato, M., Usui, D., Mogami, Y., et al. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.04.005 · Cited by 59
Coman, D. J., Sinclair, K., Cj, B., Db, A., Pelekanos, J. T., O’Neil, C., Wallace, G., Bowling, F. G., Wang, D., Vivo, D. C. D., et al. (2006) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2006.00852.x · Cited by 59
Quinidine therapy for West syndrome with KCNTI mutation: A case report
Fukuoka, M., Kuki, I., Kawawaki, H., Okazaki, S., Kim, K., Hattori, Y., Tsuji, H., Nukui, M., Inoue, T., Yoshida, Y., et al. (2016) · Brain and Development · doi:10.1016/j.braindev.2016.08.002 · Cited by 59
Wynn, J., Ottman, R., Duong, J., Wilson, A. L., Ahimaz, P., Martinez, J., Rabin, R., Rosen, E., Webster, R., Au, C., et al. (2018) · Clinical Genetics · doi:10.1111/cge.13200 · Cited by 59
Barker, B. S., Ottolini, M., Wagnon, J. L., Hollander, R. M., Meisler, M. H., & Patel, M. K. (2016) · Epilepsia · doi:10.1111/epi.13461 · Cited by 52
Nellist, M. D., Schot, R., Hoogeveen‐Westerveld, M., Neuteboom, R. F., van der Louw, E. J. T. M., Lequin, M. H., Heus, K. B., Sibbles, B. J., de Coo, I. F. M., Brooks, A. S., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.11.018 · Cited by 50
A phenotype centric benchmark of variant prioritisation tools
Anderson, D., & Lassmann, T. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0044-9 · Cited by 43
De novo SCN 1A pathogenic variants in the GEFS+ spectrum: Not always a familial syndrome
Myers, K. A., Burgess, R., Afawi, Z., Damiano, J. A., Berkovic, S. F., Hildebrand, M. S., & Scheffer, I. E. (2017) · Epilepsia · doi:10.1111/epi.13649 · Cited by 38
Developmental outcomes of childhood‐onset temporal lobe epilepsy: A community‐based study
Wilson, S. J., Micallef, S., Henderson, A., Rayner, G., Wrennall, J. A., Spooner, C. G., & Harvey, A. S. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03632.x · Cited by 31
Krabbenborg, L., Schieving, J., Kleefstra, T., Vissers, L. E. L. M., Willemsen, M. A. A. P., Veltman, J. A., & van der Burg, S. (2015) · Clinical Genetics · doi:10.1111/cge.12601 · Cited by 29
Genetic analysis of benign familial epilepsies in the first year of life in a Chinese cohort
Zeng, Q., Yang, X., Zhang, J., Liu, A., Yang, Z., Liu, X., Wu, Y., Wu, X., Wei, L., & Zhang, Y. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0359-x · Cited by 28
French, J. A., Thiele, E. A., Mazurkiewicz‐Bełdzińska, M., Benbadis, S. R., Marsh, E. D., Joshi, C., Roberts, C., Taylor, A. R., & Sommerville, K. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.s21.001 · Cited by 23
Research works printed but not linked: 1
- The Broad Institute: Cambridge MA 2018. gnomAD Browser. http://gnomad.broadinstitute.org/(April 2018, date last accessed).
Cited by
Zuberi, S. M., Wirrell, E., Yozawitz, E., Wilmshurst, J. M., Specchio, N., Riney, K., Pressler, R., Auvin, S., Samia, P., Hirsch, E., et al. (2022) · Epilepsia · doi:10.1111/epi.17239 · Cited by 934
Self-citationKlepper, J., Akman, C., Armeno, M., Auvin, S., Cervenka, M., Cross, H. J., De Giorgis, V., Della Marina, A., Engelstad, K., Heussinger, N., et al. (2020) · Epilepsia Open · doi:10.1002/epi4.12414 · Cited by 285
Self-citationMiller, I., Scheffer, I. E., Gunning, B., Sanchez-Carpintero, R., Gil-Nagel, A., Perry, M. S., Saneto, R. P., Checketts, D., Dunayevich, E., Knappertz, V., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0073 · Cited by 267
Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants
Symonds, J. D., Elliott, K. S., Shetty, J., Armstrong, M., Brunklaus, A., Cutcutache, I., Diver, L. A., Dorris, L., Gardiner, S., Jollands, A., et al. (2021) · Brain · doi:10.1093/brain/awab162 · Cited by 269
“Since PRRT2-associated epilepsy is associated with a good outcome in nearly all cases, there is little selection pressure on this gene, and in 71% of cases in our study the variant was inherited.(17) It is possible that epilepsy-associated PRRT2 variants are more prevalent in the Scottish population than other populat…”
BackgroundMethodSelf-citationDevelopmental and epileptic encephalopathies: what we do and do not know
Specchio, N., & Curatolo, P. (2021) · Brain · doi:10.1093/brain/awaa371 · Cited by 164
Metadata
- Authors
- Symonds, J. D., Zuberi, S. M., Stewart, K., McLellan, A., O‘Regan, M., MacLeod, S., Jollands, A., Joss, S., Kirkpatrick, M., Brunklaus, A., Pilz, D. T., Shetty, J., Dorris, L., Abu-Arafeh, I., Andrew, J., Brink, P., Callaghan, M., Cruden, J., Diver, L. A., Findlay, C., Gardiner, S., Grattan, R., Lang, B., MacDonnell, J., McKnight, J., Morrison, C. A., Nairn, L., Slean, M. M., Stephen, E., Webb, A., Vincent, A., & Wilson, M.
- Affiliations
- Royal Hospital for Children (GB)
- Queen Elizabeth University Hospital (GB)
- Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK
- NHS Tayside (GB)
- Department of Paediatrics, Forth Valley Royal Hospital, Larbert, UK
- Wishaw General Hospital (GB)
- Victoria Hospital (GB)
- University Hospital Crosshouse (GB)
- Forth Valley Royal Hospital (GB)
- John Radcliffe Hospital (GB)
- Borders General Hospital (GB)
- Dumfries and Galloway Royal Infirmary (GB)
- Royal Alexandra Hospital (GB)
- University of Glasgow (GB)
- Royal Aberdeen Children's Hospital (GB)
- Raigmore Hospital (GB)
- Corresponding author
- Zuberi, Sameer M
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-13
- Volume
- 142
- Issue
- 8
- Pages
- 2303-2318
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6658850
- OpenAlex
- W2961503558
- Cited by
- 459
- References
- 81
- Citations by year
- 2026: 49 · 2025: 82 · 2024: 87 · 2023: 67 · 2022: 76 · 2021: 44 · 2020: 48 · 2019: 6
- FWCI
- 34.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, cc-by-nc)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Epilepsy Research UK
- Dravet Syndrome UK
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- childhood-onset epilepsy, genetic epilepsy, incidence, phenotypic spectrum, PRRT2, SCN1A, KCNQ2, KCNQ3, KCNA2, KCNA1, Kv1.3 potassium channel, Kv1.5, KC
- MeSH terms
- Child, Preschool, Epilepsy, Female, Humans, Infant, Infant, Newborn, Male, Phenotype, Prospective Studies, Scotland, Cohort Studies, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.